Center For Scientific Review; Amended Notice of Meeting, 27883-27884 [2014-11144]
Download as PDF
<![CDATA[
TKELLEY on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 79, No. 94 / Thursday, May 15, 2014 / Notices
activity including that of PPT1.
Unfortunately, the inherent toxicity of
HA precludes its clinical use for any
disorder. The inventors evaluated
several non-toxic derivatives of HA for
anti-oxidant properties, the ability to
cleave thioester linkage in S-acylated
proteins, the ability to mediate ceroid
depletion, to suppress apoptosis in
cultured cells from INCL patients and in
Ppt1-knockout (Ppt1-/-) mice.
Specifically, the inventors have
discovered that NtBuHA is non-toxic,
manifests potent antioxidant property,
cleaves thioester linkages in S-acylated
proteins, depletes intracellular ceroid in
Ppt1-/- mice and extends lifespan.
These results demonstrated that
NtBuHA may be broadly useful as
therapeutic agents for thioesterase
deficiency disorders including INCL.
Potential Commercial Applications:
Compositions and methods to treat or
prevent thioesterase deficiency
disorders
Competitive Advantages:
• Currently there are no effective
treatments for INCL and N-t-BuHA
will be the first specific treatment
targeting INCL
• N-t-BuHA can be developed as a
broad spectrum therapeutic against
thioesterase deficiency disorders.
Development Stage: In vivo data
available (animal)
Inventors: Anil Baran Mukherjee,
Chinmoy Sarkar, Zhongjian Zhang (all
of NICHD)
Publication: Sarkar C, et al.
Neuroprotection and lifespan extension
in Ppt1(-/-) mice by NtBuHA:
therapeutic implications for INCL. Nat
Neurosci. 2013 Nov;16(11):1608–17.
[PMID 24056696]
Intellectual Property: HHS Reference
No. E–157–2011/0 –
• U.S. Patent Application No. 14/
110,393 filed 07 Oct 2013
• EP Patent Application No.
12716889.6 filed 07 Oct 2013
Licensing Contact: Suryanarayana
Vepa, Ph.D., J.D.; 301–435–5020;
vepas@mail.nih.gov
Collaborative Research Opportunity:
The Eunice Kennedy Shriver National
Institute of Child Health and Human
Development is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize hydroxylaminederivatives or other small molecules
with similar properties for treating
thioesterase deficiency diseases
including infantile neuronal ceroid
lipofuscinosis (INCL). For collaboration
opportunities, please contact Joseph M.
VerDate Mar<15>2010
18:18 May 14, 2014
Jkt 232001
Conrad, Ph.D., J.D. at jmconrad@
mail.nih.gov or 240–276–5495.
Non-Invasive In Vivo MR Method to
Image Salient Features of Nerves
Description of Technology: The
invention consists of a novel diffusion
MRI experiment and modeling
framework that describes white matter
in the central nervous system (CNS) and
nerves in the peripheral nervous system
(PNS) as composite media having intraand extra axonal spaces with different
water diffusion characteristics.
Specifically, fascicles in the nervous
system are modeled as having a
hindered extracellular region and a
restricted intracellular or intra-axonal
region. Diffusion of water in these two
distinct compartments contributes to the
total measured diffusion MRI signal.
This method provides a voxel-by-voxel
measurement of the intra- and extraaxonal volume fractions, and an
estimate of the mean axon diameter.
This technology is also incorporated in
NIH’s AxCaliber MRI technology, which
extends it, treating fascicles as a bundle
of impermeable cylinders having a
distribution of internal diameters.
The significance of this invention is
that it provides measurements of new
and useful microanatomical features of
white matter (and gray matter) that are
closely related to the function of the
nervous system—particularly the speed
that information travels along axons—
critically important in medicine and the
neurosciences. Previously, the data
provided by this non-invasive MR
imaging method were only available
using invasive and laborious
histological means requiring tissue
biopsy.
Potential Commercial Applications:
• clinical MRI
• small animal or pre-clinical MRI
Competitive Advantages:
• non-invasive, painless, in vivo
measurement of microanatomical
features of nerves and muscles.
• no contrast agents required
• modest data requirements allow for
scans to be performed in a clinically
feasible time-frame
Development Stage:
• Early-stage
• In vitro data available
• In vivo data available (animal)
• In vivo data available (human)
• In situ data available (on-site)
• Prototype
Inventors: Peter J. Basser (NICHD),
Yaniv Assaf (Tel Aviv University)
Publications:
1. Assaf Y, et al. New modeling and
experimental framework to characterize
hindered and restricted water diffusion
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
27883
in brain white matter. Magn Reson Med.
2004 Nov;52(5):965–78. [PMID
15508168]
2. Assaf Y, Basser PJ. Composite hindered
and restricted model of diffusion
(CHARMED) MR imaging of the human
brain. Neuroimage 2005 Aug 1;27(1):48–
58. [PMID 15979342]
3. Assaf Y, Basser PJ. Combining DT and qspace MRI: a new model of white matter
in the brain. In Proc. Intl. Soc. Mag.
Reson. Med. 2003;11:588. [https://
cds.ismrm.org/ismrm-2003/ismrm03.pdf]
4. Assaf Y, et al. A New Modeling and
Experimental Framework to Characterize
Hindered and Restricted Water Diffusion
in Brain White Matter. In Proc. Intl. Soc.
Mag. Reson. Med. 2004;11:251. [https://
cds.ismrm.org/ismrm-2004/Files/
Program04.pdf]
Intellectual Property: HHS Reference
No. E–079–2003/1—US Patent No.
8,380,280 filed 19 Feb 2013
Related Technologies:
• HHS Reference No. E–203–
1993/0—U.S. Patent No. 5,539,310
issued 23 Jul 1996
• HHS Reference No. E–079–
2003/0—U.S. Patent No. 7,643,863
issued 05 Jan 2010
• HHS Reference No. E–276–2008/
0—U.S. Patent No. 8,704,515 issued 22
Apr 2014
Licensing Contact: John Stansberry,
Ph.D.; 301–435–5236;
stansbej@mail.nih.gov
Collaborative Research Opportunity:
The Eunice Kennedy Shriver National
Institute of Child Health and Human
Development is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize novel MRI methods to
probe tissue structure and organization,
particularly for neuroimaging
applications. For collaboration
opportunities, please contact Alan E.
Hubbs at hubbsa@mail.nih.gov or 240–
276–5530.
Dated: May 12, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2014–11146 Filed 5–14–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center For Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Clinical and
Integrative Diabetes and Obesity Study
E:\FR\FM\15MYN1.SGM
15MYN1
27884
Federal Register / Vol. 79, No. 94 / Thursday, May 15, 2014 / Notices
Section, June 05, 2014, 08:00 a.m. to
June 06, 2014, 06:00 p.m., Residence Inn
Bethesda, 7335 Wisconsin Avenue,
Bethesda, MD, 20814 which was
published in the Federal Register on
May 07, 2014, 79 FR 26261.
The meeting will be held on June 5,
2014. The meeting location and time
remain the same. The meeting is closed
to the public.
Dated: May 9, 2014.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–11144 Filed 5–14–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
TKELLEY on DSK3SPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Neural Trauma, Stroke and
Epilepsy.
Date: June 6, 2014.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Alexei Kondratyev,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5200,
MSC 7846, Bethesda, MD 20892, 301–435–
1785, kondratyevad@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Cancer,
Cardiovascular, and Sleep Epidemiology
Panel A.
Date: June 9, 2014.
Time: 8:00 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW.,
Washington, DC 20015.
VerDate Mar<15>2010
18:18 May 14, 2014
Jkt 232001
Contact Person: Denise Wiesch, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3138,
MSC 7770, Bethesda, MD 20892, (301) 437–
3478, wieschd@csr.nih.gov.
Name of Committee: Integrative,
Functional and Cognitive Neuroscience
Integrated Review Group;
Neuroendocrinology, Neuroimmunology,
Rhythms and Sleep Study Section.
Date: June 9–10, 2014.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Admiral Fell Inn, 888 South
Broadway, Baltimore, MD 21231.
Contact Person: Michael Selmanoff, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5164,
MSC 7844, Bethesda, MD 20892, 301–435–
1119, mselmanoff@csr.nih.gov.
Name of Committee: Oncology 2—
Translational Clinical Integrated Review
Group; Clinical Oncology Study Section.
Date: June 9, 2014.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Sir Francis Drake Hotel, 450 Powell
Street at Sutter, San Francisco, CA 94102.
Contact Person: Malaya Chatterjee, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6192,
MSC 7804, Bethesda, MD 20892, 301–806–
2515, chatterm@csr.nih.gov.
Name of Committee: Integrative,
Functional and Cognitive Neuroscience
Integrated Review Group; Somatosensory and
Chemosensory Systems Study Section.
Date: June 10–11, 2014.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites DC Convention
Center, 900 10th Street NW., Washington, DC
20001.
Contact Person: M Catherine Bennett,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5182,
MSC 7846, Bethesda, MD 20892, 301–435–
1766, bennettc3@csr.nih.gov.
Name of Committee: Bioengineering
Sciences & Technologies Integrated Review
Group; Modeling and Analysis of Biological
Systems Study Section.
Date: June 10, 2014.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Craig Giroux, Ph.D.,
Scientific Review Officer, BST IRG, Center
for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5150,
Bethesda, MD 20892, 301–435–2204,
girouxcn@csr.nih.gov.
Name of Committee: Interdisciplinary
Molecular Sciences and Training Integrated
Review Group; Enabling Bioanalytical and
Imaging Technologies Study Section.
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
Date: June 10–11, 2014.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Renaissance Washington DC,
Dupont Circle, 1143 New Hampshire Avenue
NW., Washington, DC 20037.
Contact Person: Dennis Hlasta, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6185,
MSC 7892, Bethesda, MD 20892, 301–435–
1047, dennis.hlasta@nih.gov.
Name of Committee: Biology of
Development and Aging Integrated Review
Group; International and Cooperative
Projects—1 Study Section.
Date: June 10, 2014.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Manhattan Beach Marriott Hotel and
Golf Club, 1400 Parkview Avenue,
Manhattan Beach, CA 90266.
Contact Person: Hilary D. Sigmon, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5222,
MSC 7852, Bethesda, MD 20892, (301) 594–
6377, sigmonh@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA Panel:
Investigations on Primary Immunodeficiency
Diseases.
Date: June 10, 2014.
Time: 11:30 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Scott Jakes, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4198,
MSC 7812, Bethesda, MD 20892, 301–495–
1506, jakesse@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–14–
008: Secondary Analysis to Explore NIMH
Research Domain Criteria.
Date: June 10, 2014.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Julius Cinque, MS,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5186,
MSC 7846, Bethesda, MD 20892, (301) 435–
1252, cinquej@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflicts: Liver and Gastrointestinal
Physiology and Pathophysiology.
Date: June 10, 2014.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
E:\FR\FM\15MYN1.SGM
15MYN1
]]>Agencies
[Federal Register Volume 79, Number 94 (Thursday, May 15, 2014)]
[Notices]
[Pages 27883-27884]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-11144]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center For Scientific Review; Amended Notice of Meeting
Notice is hereby given of a change in the meeting of the Clinical
and Integrative Diabetes and Obesity Study
[[Page 27884]]
Section, June 05, 2014, 08:00 a.m. to June 06, 2014, 06:00 p.m.,
Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda, MD, 20814
which was published in the Federal Register on May 07, 2014, 79 FR
26261.
The meeting will be held on June 5, 2014. The meeting location and
time remain the same. The meeting is closed to the public.
Dated: May 9, 2014.
Carolyn Baum,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2014-11144 Filed 5-14-14; 8:45 am]
BILLING CODE 4140-01-P
